Since there is still a lack of targeted therapies in TNBC, the uPA system as well as novel interacting partners of uPAR or associated proteins are of great interest as candidates for therapeutic biomarkers in this aggressive tumor entity. The gene discussed is PLAU; the disease is neoplasm.